Investor Presentaiton
Consolidated Financials
J Sequent
All values in Mn
Proven Ability In Life Sciences
ALIVIRA
Q4 FY23
Particulars
Unaudited
Q3 FY23
Unaudited
Q4 FY22
Unaudited
FY23
Audited
FY22
Audited
Revenue from Operations
3,667
3,753
3,837
14,209
14,128
Material Consumption
(2,217)
(2,174)
(2,188)
(8,338)
(7,930)
Gross Margin
1,449
1,579
1,649
5,871
6,198
%
39.5%
42.1%
43.0%
41.3%
43.9%
Employee Benefit Expenses
(570)
(580)
(519)
(2,230)
(1,985)
Impact on gross
Operating Expenses
(751)
(722)
(744)
(2,886)
(2,791)
EBITDA (pre ESOP)
128
277
386
756
1,423
%
3.5%
7.4%
10.1%
5.3%
10.1%
margin due to
reduction in
Inventory
ESOP cost
(76)
(89)
(53)
(354)
(329)
OPEX controlled
EBITDA
52
188
333
402
1,094
%
1.4%
5.0%
8.7%
2.8%
7.7%
Exceptional Items / Acquisition cost*
(616)
(10)
(658)
IndAS 29 Adjustment
(56)
(28)
(158)
Exchange Gain / (Loss)
(30)
(46)
23
(114)
63
Other Income
17
29
15
64
45
Finance Cost
Depreciation
(109)
(97)
(60)
(355)
(158)
(147)
(137)
(125)
(557)
(515)
despite inflationary
pressure
Exceptional items
driven by closure of
plant in Germany
and impact of recent
events in Turkey
Taxes
Earnings Before Tax
Earnings After Tax
Minority Interest
Earnings after Minority Interest
(888)
(102)
186
(1,377)
529
(36)
4
(86)
157
(83)
(924)
(98)
100
(1,220)
446
11
(9)
11
(8)
38
(936)
(89)
90
(1,212)
408
*
Q3 FY23 10 Mn acquisition related cost
6View entire presentation